Comparing outcomes of meropenem administration strategies 2010eduardo de avila
This document systematically reviews evidence comparing traditional and alternative dosing strategies for meropenem. Sixteen studies were reviewed, including 13 pharmacokinetic/dynamic assessments, 5 clinical evaluations, and 3 economic appraisals. Studies suggest alternative dosing strategies like prolonged or continuous infusion may increase achieving pharmacodynamic targets compared to traditional dosing. However, evidence linking these strategies to improved clinical outcomes is lacking. Smaller, more frequent doses appear to provide similar clinical outcomes and pharmacodynamic target attainment as traditional dosing, with potential cost savings. Overall, alternative dosing strategies seem to provide comparable outcomes to traditional dosing, but evidence is limited and largely based on healthy subjects. Larger clinical trials are needed.
The document discusses marketing trends over time from the Production Era to today's Marketing Concept Era where customer satisfaction is emphasized. It also discusses changing approaches like focusing on the 7Ps of marketing (Product, Price, Place, Promotion, Physical Layout, Provision for customer service, and Processes) instead of just the traditional 4Ps. Finally, it talks about emerging trends in experiential marketing using technologies like social media, augmented reality, and projection mapping.
The document discusses the key differences between being self-employed and starting a growth business. Self-employed individuals need skills, contacts, confidence and basic business knowledge to turn their expertise into services, while entrepreneurs require a team, large market opportunities, validated business models, and investment to build scalable and profitable businesses. It also outlines the traditional startup model and challenges therein, and promotes a new customer-focused model involving understanding problems, testing minimum viable products, and fostering customer love and retention to drive growth.
New frontiers in healthcare access: m-Health
The document discusses trends in mobile health (m-Health) and opportunities for growth. It notes that m-Health market size is growing significantly and that demand is increasing due to a rise in chronic diseases and a shift to patient-centered care. By 2020, m-Health is projected to enable remote consultations and monitoring, self-testing and management of diseases. Key drivers of m-Health include rising incomes, technology advances, and a growing focus on home healthcare. Barriers include developing effective revenue models and gaining physician acceptance. New m-Health technologies discussed include solutions for cardiology, imaging, home care, surgery and women's health. Digital initiatives and public-private
Digital health trends in Asia present business opportunities for mHealth companies. By 2020, chronic diseases will affect two-thirds of Asia Pacific's population over 65 years old. Key drivers for mHealth business include rising incomes, lifestyle diseases, mobile penetration, and patient self-management. Barriers include developing revenue models and gaining medical acceptance. Successful mHealth companies target specific customer segments with technologies tailored for areas like cardiology, imaging, and women's health. Partnerships through initiatives like India's Digital India program can help companies reach customers and grow their business.
BPL LifePhone Plus is a device that can attach to a smartphone and transform it into a personal health monitoring system. It can measure ECG, blood glucose, pulse rate, calories burned, and activity levels. The data is displayed on the smartphone and can be shared with doctors in real-time for remote monitoring and feedback. The device is validated for use by cardiac and diabetic patients to routinely monitor health metrics and receive guidance from physicians. It aims to make healthcare more convenient and accessible wherever patients are located.
Comparing outcomes of meropenem administration strategies 2010eduardo de avila
This document systematically reviews evidence comparing traditional and alternative dosing strategies for meropenem. Sixteen studies were reviewed, including 13 pharmacokinetic/dynamic assessments, 5 clinical evaluations, and 3 economic appraisals. Studies suggest alternative dosing strategies like prolonged or continuous infusion may increase achieving pharmacodynamic targets compared to traditional dosing. However, evidence linking these strategies to improved clinical outcomes is lacking. Smaller, more frequent doses appear to provide similar clinical outcomes and pharmacodynamic target attainment as traditional dosing, with potential cost savings. Overall, alternative dosing strategies seem to provide comparable outcomes to traditional dosing, but evidence is limited and largely based on healthy subjects. Larger clinical trials are needed.
The document discusses marketing trends over time from the Production Era to today's Marketing Concept Era where customer satisfaction is emphasized. It also discusses changing approaches like focusing on the 7Ps of marketing (Product, Price, Place, Promotion, Physical Layout, Provision for customer service, and Processes) instead of just the traditional 4Ps. Finally, it talks about emerging trends in experiential marketing using technologies like social media, augmented reality, and projection mapping.
The document discusses the key differences between being self-employed and starting a growth business. Self-employed individuals need skills, contacts, confidence and basic business knowledge to turn their expertise into services, while entrepreneurs require a team, large market opportunities, validated business models, and investment to build scalable and profitable businesses. It also outlines the traditional startup model and challenges therein, and promotes a new customer-focused model involving understanding problems, testing minimum viable products, and fostering customer love and retention to drive growth.
New frontiers in healthcare access: m-Health
The document discusses trends in mobile health (m-Health) and opportunities for growth. It notes that m-Health market size is growing significantly and that demand is increasing due to a rise in chronic diseases and a shift to patient-centered care. By 2020, m-Health is projected to enable remote consultations and monitoring, self-testing and management of diseases. Key drivers of m-Health include rising incomes, technology advances, and a growing focus on home healthcare. Barriers include developing effective revenue models and gaining physician acceptance. New m-Health technologies discussed include solutions for cardiology, imaging, home care, surgery and women's health. Digital initiatives and public-private
Digital health trends in Asia present business opportunities for mHealth companies. By 2020, chronic diseases will affect two-thirds of Asia Pacific's population over 65 years old. Key drivers for mHealth business include rising incomes, lifestyle diseases, mobile penetration, and patient self-management. Barriers include developing revenue models and gaining medical acceptance. Successful mHealth companies target specific customer segments with technologies tailored for areas like cardiology, imaging, and women's health. Partnerships through initiatives like India's Digital India program can help companies reach customers and grow their business.
BPL LifePhone Plus is a device that can attach to a smartphone and transform it into a personal health monitoring system. It can measure ECG, blood glucose, pulse rate, calories burned, and activity levels. The data is displayed on the smartphone and can be shared with doctors in real-time for remote monitoring and feedback. The device is validated for use by cardiac and diabetic patients to routinely monitor health metrics and receive guidance from physicians. It aims to make healthcare more convenient and accessible wherever patients are located.
BPL LifePhone Plus is a device that can attach to a smartphone and transform it into a personal health monitoring system. It can measure ECG, blood glucose, pulse rate, calories burned, and activity levels. The data is displayed on the smartphone and can be shared with doctors in real-time for remote monitoring and feedback. The device is validated for use by cardiac and diabetic patients to routinely monitor their health from home or on the go. It aims to improve wellness through self-management and reduce healthcare costs through remote care and prevention.
BPL LifePhone Plus is a mobile health monitoring device that allows users to record an ECG and monitor vital signs like heart rate and activity level. The data is transmitted via Bluetooth to a smartphone app where it can be shared with doctors for remote consultation. Specialists can provide instant feedback and advice through the app. The device aims to make quality healthcare more accessible and convenient for users by allowing remote patient monitoring and consultations from anywhere at any time.
Telehealth and mHealth programs in India and South Asia are growing due to several factors:
1) Increasing rates of lifestyle diseases like cardiovascular disease and cancer due to more sedentary jobs and higher spending.
2) Demand for healthcare is increasing due to growing consumerism, insurance coverage, quality expectations, and awareness of clinical decisions.
3) mHealth solutions like BPL Medical's Lifephone Plus allow for remote monitoring of patients' ECGs and activity to provide timely medical advice and management of chronic conditions. The small, easy-to-use device connects to a smartphone app for specialists to remotely analyze readings.
- The document compares the two carbapenem antibiotics imipenem/cilastatin and meropenem. While meropenem was once thought to be superior, clinical evidence and studies now indicate the two drugs are therapeutically equivalent.
- Imipenem/cilastatin may have some advantages over meropenem for certain infections and patient populations based on lower resistance rates, better clinical outcomes, and potentially lower cost in some cases. However, both remain important treatment options for many multidrug-resistant infections.
The document discusses the role of DPP-4 inhibition and sitagliptin in the management of type 2 diabetes. It provides evidence that sitagliptin increases active GLP-1 and GIP levels, resulting in improved glycemic control through increased insulin secretion, decreased glucagon levels, and reduced glucose levels. Studies show sitagliptin to be an effective monotherapy and when added to other oral medications, with benefits seen within days and a generally well-tolerated safety profile compared to sulfonylureas.
The document discusses sitagliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes. It describes how DPP-4 inhibition increases levels of active incretin hormones GLP-1 and GIP, improving glycemic control. Clinical trials showed sitagliptin is a potent, selective, and reversible DPP-4 inhibitor. It provides >80% inhibition of DPP-4 with once-daily dosing, increasing active incretin levels and insulin secretion while decreasing glucagon. Sitagliptin treatment was well-tolerated and improved glycemic control in patients with type 2 diabetes.
The document discusses type 2 diabetes and the role of incretin hormones like GLP-1 and GIP. It notes that patients with type 2 diabetes have impaired secretion and actions of incretins. Dipeptidyl peptidase-4 (DPP-4) inhibitors work by blocking the degradation of incretins, thereby increasing their levels and effects. Clinical trials show that sitagliptin (Januvia), a DPP-4 inhibitor, improves glycemic control in type 2 diabetes patients by enhancing the actions of endogenous GLP-1 and GIP.
BPL LifePhone Plus is a device that can attach to a smartphone and transform it into a personal health monitoring system. It can measure ECG, blood glucose, pulse rate, calories burned, and activity levels. The data is displayed on the smartphone and can be shared with doctors in real-time for remote monitoring and feedback. The device is validated for use by cardiac and diabetic patients to routinely monitor their health from home or on the go. It aims to improve wellness through self-management and reduce healthcare costs through remote care and prevention.
BPL LifePhone Plus is a mobile health monitoring device that allows users to record an ECG and monitor vital signs like heart rate and activity level. The data is transmitted via Bluetooth to a smartphone app where it can be shared with doctors for remote consultation. Specialists can provide instant feedback and advice through the app. The device aims to make quality healthcare more accessible and convenient for users by allowing remote patient monitoring and consultations from anywhere at any time.
Telehealth and mHealth programs in India and South Asia are growing due to several factors:
1) Increasing rates of lifestyle diseases like cardiovascular disease and cancer due to more sedentary jobs and higher spending.
2) Demand for healthcare is increasing due to growing consumerism, insurance coverage, quality expectations, and awareness of clinical decisions.
3) mHealth solutions like BPL Medical's Lifephone Plus allow for remote monitoring of patients' ECGs and activity to provide timely medical advice and management of chronic conditions. The small, easy-to-use device connects to a smartphone app for specialists to remotely analyze readings.
- The document compares the two carbapenem antibiotics imipenem/cilastatin and meropenem. While meropenem was once thought to be superior, clinical evidence and studies now indicate the two drugs are therapeutically equivalent.
- Imipenem/cilastatin may have some advantages over meropenem for certain infections and patient populations based on lower resistance rates, better clinical outcomes, and potentially lower cost in some cases. However, both remain important treatment options for many multidrug-resistant infections.
The document discusses the role of DPP-4 inhibition and sitagliptin in the management of type 2 diabetes. It provides evidence that sitagliptin increases active GLP-1 and GIP levels, resulting in improved glycemic control through increased insulin secretion, decreased glucagon levels, and reduced glucose levels. Studies show sitagliptin to be an effective monotherapy and when added to other oral medications, with benefits seen within days and a generally well-tolerated safety profile compared to sulfonylureas.
The document discusses sitagliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes. It describes how DPP-4 inhibition increases levels of active incretin hormones GLP-1 and GIP, improving glycemic control. Clinical trials showed sitagliptin is a potent, selective, and reversible DPP-4 inhibitor. It provides >80% inhibition of DPP-4 with once-daily dosing, increasing active incretin levels and insulin secretion while decreasing glucagon. Sitagliptin treatment was well-tolerated and improved glycemic control in patients with type 2 diabetes.
The document discusses type 2 diabetes and the role of incretin hormones like GLP-1 and GIP. It notes that patients with type 2 diabetes have impaired secretion and actions of incretins. Dipeptidyl peptidase-4 (DPP-4) inhibitors work by blocking the degradation of incretins, thereby increasing their levels and effects. Clinical trials show that sitagliptin (Januvia), a DPP-4 inhibitor, improves glycemic control in type 2 diabetes patients by enhancing the actions of endogenous GLP-1 and GIP.